Jason Drew Smith - 31 Aug 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
General Counsel
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Aug 2023
Net transactions value
-$68,438
Form type
4
Filing time
05 Sep 2023, 16:28:18 UTC
Previous filing
02 Feb 2023
Next filing
08 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +8,334 +60% 22,207 31 Aug 2023 Direct F1
transaction URGN Ordinary Shares Sale $68,438 -3,800 -17% $18.01 18,407 31 Aug 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -8,334 -100% $0.000000* 0 31 Aug 2023 Ordinary Shares 8,334 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vested in three equal installments on November 30, 2021, August 31, 2022 and August 31, 2023.